Stocks and Investing
Stocks and Investing
Tue, May 24, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Paul Choi Maintained (BBIO) at Strong Buy with Decreased Target to $19 on, May 24th, 2022
Paul Choi of Goldman Sachs, Maintained "BridgeBio Pharma, Inc." (BBIO) at Strong Buy with Decreased Target from $24 to $19 on, May 24th, 2022.
Paul has made no other calls on BBIO in the last 4 months.
There are 3 other peers that have a rating on BBIO. Out of the 3 peers that are also analyzing BBIO, 0 agree with Paul's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Paul
- Mani Foroohar of "SVB Leerink" Maintained at Buy with Increased Target to $27 on, Friday, May 6th, 2022
- Raghuram Selvaraju of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $22 on, Wednesday, March 16th, 2022
- Anupam Rama of "JP Morgan" Maintained at Buy with Decreased Target to $18 on, Friday, March 11th, 2022
Contributing Sources